Open-label, single-arm phase Ib/II study of immune combination therapy with elotuzumab and belantamab mafodotin in patients with relapsed refractory multiple myeloma

被引：0
|
作者：
Browning, Sabrina
Li, Fangyong
Parker, Terri L.
Bar, Noffar
Anderson, Tara
Stevens, Erica
VanOudenhove, Jennifer
Matthews, Martin
Gorshein, Elan
Talsania, Ashita D.
Sabbath, Kert D.
Seropian, Stuart
Halene, Stephanie
Neparidze, Natalia
机构：
[1] Yale Sch Med, Div Hematol, Dept Internal Med, New Haven, CT USA
[2] Yale Sch Publ Hlth, New Haven, CT USA
[3] Yale New Haven Hosp, New Haven, CT USA
[4] Yale Univ, Div Hematol, New Haven, CT USA
[5] Yale Canc Ctr, Div Hematol, New Haven, CT USA
[6] Yale Univ, Div Hematol, Shool Med, New Haven, CT USA
[7] Yale Univ, New Haven, CT USA
[8] Yale Univ, Yale Canc Ctr, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7559
引用
收藏
页数：1
相关论文
共 50 条
  • [1] DREAMM 4: A phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)
    Trudel, S.
    Nooka, A.
    Fecteau, D.
    Talekar, M.
    Jewell, R. C.
    Williams, D.
    Evans, J.
    Opalinska, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [2] Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
    Lonial, Sagar
    Lee, Hans C.
    Badros, Ashraf
    Trudel, Suzanne
    Nooka, Ajay K.
    Chari, Ajai
    Abdallah, Al-Ola
    Callander, Natalie
    Lendvai, Nikoletta
    Sborov, Douglas
    Suvannasankha, Attaya
    Weisel, Katja
    Karlin, Lionel
    Libby, Edward
    Arnulf, Bertrand
    Facon, Thierry
    Hulin, Cyrille
    Kortum, K. Martin
    Rodriguez-Otero, Paula
    Usmani, Saad Z.
    Hari, Parameswaran
    Baz, Rachid
    Hang Quach
    Moreau, Philippe
    Voorhees, Peter M.
    Gupta, Ira
    Hoos, Axel
    Zhi, Eric
    Baron, January
    Piontek, Trisha
    Lewis, Eric
    Jewell, Roxanne C.
    Dettman, Elisha J.
    Popat, Rakesh
    Esposti, Simona Degli
    Opalinska, Joanna
    Richardson, Paul
    Cohen, Adam D.
    LANCET ONCOLOGY, 2020, 21 (02): : 207 - 221
  • [3] A PHASE II SINGLE-ARM SAFETY STUDY OF ELOTUZUMAB IN COMBINATION WITH THALIDOMIDE AND LOW DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
    Mateos, M. V.
    Granell, M.
    Oriol Rocafiguera, A.
    Martinez Lopez, J.
    Blade, J.
    Hernandez, M. T.
    Martin Sanchez, J.
    Gironella, M.
    Lynch, M.
    Bleickardt, E.
    Paliwal, P.
    Singhal, A.
    San Miguel, J.
    HAEMATOLOGICA, 2014, 99 : 361 - 362
  • [4] Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma
    Suzuki, Kenshi
    Sunami, Kazutaka
    Matsumoto, Morio
    Maki, Akio
    Shimada, Fumika
    Suzuki, Kazuyuki
    Shimizu, Kazuyuki
    ACTA HAEMATOLOGICA, 2021, 144 (03) : 264 - 274
  • [5] Open-Label, Single-Arm, Phase II Study of Everolimus in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma
    Johnston, Patrick B.
    Pinter-Brown, Lauren
    Rogerio, Jaqueline
    Warsi, Ghulam
    Graham, Anne
    Ramchandren, Radhakrishnan
    BLOOD, 2011, 118 (21) : 1169 - 1169
  • [6] A Single-Arm, Open-Label, Multi-Center Phase I/II Study Of The Combination Of Panobinostat and Carfilzomib In Patients (pts) With Relapsed Or Relapse/Refractory Multiple Myeloma (MM)
    Berdeja, Jesus
    Savona, Michael
    Mace, Joseph R.
    Hart, Lowell
    Essell, James
    Owera, Rami
    Arrowsmith, Edward
    Flinn, Ian
    BLOOD, 2013, 122 (21)
  • [7] A single-arm, open-label, multicenter phase I/II study of the combination of panobinostat (pan) and carfilzomib (cfz) in patients (pts) with relapsed/refractory multiple myeloma (RR MM).
    Berdeja, Jesus G.
    Mace, Joseph
    Lamar, Ruth E.
    Gian, Victor
    Murphy, Patrick Brian
    Patel, Manish R.
    Hart, Lowell L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] PRELIMINARY DATA OF THE ONGOING OPEN-LABEL, SINGLE-ARM PHASE II STUDY OF MP0250 IN COMBINATION WITH BORTEZOMIB plus DEXAMETHASONE IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
    Goldschmidt, H.
    Raab, M. S.
    Duerig, J.
    Szarejko, M.
    Jurczyszyn, A.
    Grzasko, N.
    Vacca, A.
    Bringhen, S.
    D'Agostino, M.
    Gamberi, B.
    Haunschild, J.
    Hermann, F.
    Fiedler, U.
    Dawson, K.
    Harstrick, A.
    Acosta, J.
    Schreder, M.
    Knop, S.
    HAEMATOLOGICA, 2018, 103 : 13 - 13
  • [9] A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF BORTEZOMIB AND DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Jakubowiak, A.
    Offidani, M.
    Pegourie, B.
    De La Rubia, J.
    Garderet, L.
    Laribi, K.
    Bosi, A.
    Marasca, R.
    Laubach, J.
    Mohrbacher, A.
    Carella, A. M.
    Singhal, A. K.
    Tsao, L. C.
    Lynch, M.
    Bleickardt, E.
    Jou, Y. M.
    Palumbo, A.
    HAEMATOLOGICA, 2015, 100 : 2 - 2
  • [10] Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma
    Mateos, Maria-Victoria
    Granell, Miguel
    Oriol, Albert
    Martinez-Lopez, Joaquin
    Blade, Joan
    Hernandez, Miguel T.
    Martin, Jesus
    Gironella, Mercedes
    Lynch, Mark
    Bleickardt, Eric
    Paliwal, Prashni
    Singhal, Anil
    San-Miguel, Jesus
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 175 (03) : 448 - 456
12345